The following are studies that used ADDRESS-2 to find and contact candidates:


The effect of anti-IL-21 and liraglutide in newly diagnosed type 1 diabetes

No longer recruiting

Summary
This study will investigate if a new drug called NNC01140006 (Anti-IL-21) when given together with another drug marketed for type 2 diabetes called liraglutide (Victoza®) can preserve the beta cells in subjects diagnosed with type 1 diabetes.


MultiPepT1Deliu-vaccine

No longer recruiting
multipept1de-logo

Summary
Trial of a potential vaccine for type 1 diabetes for adults aged 18-45 years, within 4 years of diagnosis.
www.multipeptide.co.uk

Aim
To investigate the possibility of slowing the progression of type 1 diabetes using a “vaccine”. The vaccine is made from fragments of the protein molecules found in the beta cells of the pancreas, called peptides. The aim is to re-train the immune system so that it stops recognising beta cells as a target to attack. The current study is testing the safety of the vaccine as well as its effects on the immune system.

Who is running this study?
This study is academically led and is being run by Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. The Chief Investigator is Dr Jake Powrie.

It is funded by a grant from UCB Pharma.


Adaptive study of IL-2 dose frequency on regulatory T Cells in Type 1 Diabetes (DILfrequency)DILfreq_image1

No longer recruiting

Summary
Trial for people aged 18-70 within 5 years of diagnosis, investigating a new medication called aldersleukin (interleukin-2) for use in type 1 diabetes.
www.clinical-trials-type1-diabetes.com

Aim
The research team are investigating whether this medication can halt the damage to the pancreas of people recently diagnosed with  type 1 diabetes and if so, how often the drug is required for the best results.

Who ran this study?
This study was run by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. The Chief Investigator was Dr Frank Waldron-Lynch.

It was funded by the Sir Jules Thorn Charitable Trust.


The effect of lixisenatide in type 1 diabetes study (Lixi study)NIHR - Ipswich Hospital Diabetes Childrens Clinic

No longer recruiting

Summary
Study using a glucose-lowering drug called lixisenatide that has been licenced in Europe for use in type 2 diabetes. This study is looking to see how the same drug affects people with type 1 diabetes and is for adults aged 18-70 years with a diabetes duration of 12 months or more.

Aim
To find out whether a daily injection of lixisenatide, along with prescribed insulin treatment, can improve blood sugar control in people with type 1 diabetes. Also to find out if there is a difference between participants with low insulin production from the pancreas and those who do not produce insulin from the pancreas.

Who is ran this study?
This was an academic-led study was run by a team within the Oxford Centre for Diabetes Endocrinology and Metabolism (OCDEM) and funded by an educational grant from Sanofi. The Chief Investigator was Professor Stephen Gough, Consultant Physician.